FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287218119> ?p ?o ?g. }

• W4287218119 endingPage "625" @default.
• W4287218119 startingPage "609" @default.
• W4287218119 abstract "Introduction REDUCE-IT demonstrated that adding 4 g/day of icosapent ethyl (IPE; purified ethyl ester of eicosapentaenoic acid [EPA]) to statins substantially reduced cardiovascular disease (CVD) events, with few adverse effects. These data prompted numerous leading medical societies across five continents, including the American College of Cardiology, the European Society of Cardiology, and the Japanese Circulation Society, to update their guidelines or scientific/consensus statements to recommend use of IPE for primary and secondary prevention of CVD events.Areas Covered This review discusses the incorporation of IPE into international guidelines and scientific statements, noting areas of consensus and distinction. As background, this review also describes the CVD benefits and risks of IPE as a statin adjunct, and outlines current data regarding the potential mechanisms of CVD risk reduction by EPA (as IPE) beyond triglyceride reduction.Expert Opinion/Commentary IPE is unique among ‘triglyceride-lowering’ treatments in having strong CVD outcomes data and, therefore, a broad international consensus among professional medical society guidelines and statements endorsing its use for CVD risk reduction in patients generally meeting REDUCE-IT inclusion criteria. IPE should be considered for CVD prevention as a statin adjunct in all such patients.Plain Language SummaryCardiovascular disease (CVD) remains the leading cause of death worldwide. Statin monotherapy is conventionally used first-line to reduce the risk of CV events, such as heart attacks and strokes, in patients with elevated cholesterol. However, considerable risk remains despite appropriate control of cholesterol levels with a statin. Consequently, research has focused on treatment of additional therapeutic targets to reduce this remaining CV risk. One such target is elevated blood triglyceride levels. Unfortunately, most drugs that lower triglyceride levels, such as niacin, fibrates, and mixed omega-3 fatty acids, have not reduced the risk of cardiovascular events in clinical trials when added to statin therapy. However, the omega-3 fatty acid eicosapentaenoic acid (‘EPA’) administered in highly purified form as icosapent ethyl (IPE) has emerged as the first omega-3 fatty acid, and the first triglyceride-lowering agent to prevent CV events when added to statins. This was demonstrated most notably in the pivotal REDUCE-IT trial, in which IPE reduced the risk of major CV events by 25% in high-risk patients with mildly to moderately elevated triglyceride levels despite statin-controlled cholesterol levels. The mechanisms responsible for this reduction in CV events appear to go far beyond lowering triglyceride levels alone. In light of the positive results from the REDUCE-IT trial, IPE was approved for CV disease risk reduction globally, including in the United States, Canada, European Union, and the United Kingdom, and its use is being increasingly endorsed in United States and international statements and guidelines for managing CV risk. Despite minor differences among guidelines, there is strong consensus that IPE should be considered for use in CVD prevention in all patients who meet the proposed criteria." @default.
• W4287218119 created "2022-07-25" @default.
• W4287218119 creator A5015234811 @default.
• W4287218119 creator A5020230532 @default.
• W4287218119 creator A5021777258 @default.
• W4287218119 creator A5037652425 @default.
• W4287218119 creator A5047727928 @default.
• W4287218119 creator A5080414941 @default.
• W4287218119 creator A5080753934 @default.
• W4287218119 creator A5091523473 @default.
• W4287218119 date "2022-07-28" @default.
• W4287218119 modified "2023-10-16" @default.
• W4287218119 title "Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements" @default.
• W4287218119 cites W1556346244 @default.
• W4287218119 cites W1560062315 @default.
• W4287218119 cites W1856460279 @default.
• W4287218119 cites W1973611043 @default.
• W4287218119 cites W1975997252 @default.
• W4287218119 cites W1984756098 @default.
• W4287218119 cites W1986111942 @default.
• W4287218119 cites W2001485911 @default.
• W4287218119 cites W2003532869 @default.
• W4287218119 cites W2018259829 @default.
• W4287218119 cites W2025444929 @default.
• W4287218119 cites W2026310866 @default.
• W4287218119 cites W2040770080 @default.
• W4287218119 cites W2045144594 @default.
• W4287218119 cites W2045278676 @default.
• W4287218119 cites W2048776656 @default.
• W4287218119 cites W2049641685 @default.
• W4287218119 cites W2071755201 @default.
• W4287218119 cites W2072308924 @default.
• W4287218119 cites W2084878756 @default.
• W4287218119 cites W2088149055 @default.
• W4287218119 cites W2100698037 @default.
• W4287218119 cites W2107271450 @default.
• W4287218119 cites W2107295258 @default.
• W4287218119 cites W2108169164 @default.
• W4287218119 cites W2112710165 @default.
• W4287218119 cites W2114867133 @default.
• W4287218119 cites W2124481954 @default.
• W4287218119 cites W2130654433 @default.
• W4287218119 cites W2134172530 @default.
• W4287218119 cites W2137983259 @default.
• W4287218119 cites W2142347023 @default.
• W4287218119 cites W2150420078 @default.
• W4287218119 cites W2150959326 @default.
• W4287218119 cites W2154061926 @default.
• W4287218119 cites W2155598961 @default.
• W4287218119 cites W2159449551 @default.
• W4287218119 cites W2164324917 @default.
• W4287218119 cites W2165605025 @default.
• W4287218119 cites W2167141436 @default.
• W4287218119 cites W2189339462 @default.
• W4287218119 cites W2192223169 @default.
• W4287218119 cites W2290053204 @default.
• W4287218119 cites W2314793531 @default.
• W4287218119 cites W2328529137 @default.
• W4287218119 cites W2330486239 @default.
• W4287218119 cites W2336847247 @default.
• W4287218119 cites W2341439667 @default.
• W4287218119 cites W2341665659 @default.
• W4287218119 cites W2345269362 @default.
• W4287218119 cites W2485118186 @default.
• W4287218119 cites W2527894800 @default.
• W4287218119 cites W2535158955 @default.
• W4287218119 cites W2592571300 @default.
• W4287218119 cites W2614282478 @default.
• W4287218119 cites W2681957878 @default.
• W4287218119 cites W2753496867 @default.
• W4287218119 cites W2773247353 @default.
• W4287218119 cites W2783002547 @default.
• W4287218119 cites W2800627035 @default.
• W4287218119 cites W2808724025 @default.
• W4287218119 cites W2885602607 @default.
• W4287218119 cites W2899669642 @default.
• W4287218119 cites W2899720772 @default.
• W4287218119 cites W2900151286 @default.
• W4287218119 cites W2902364078 @default.
• W4287218119 cites W2905997876 @default.
• W4287218119 cites W2913507355 @default.
• W4287218119 cites W2921370002 @default.
• W4287218119 cites W2925924778 @default.
• W4287218119 cites W2950227430 @default.
• W4287218119 cites W2965789849 @default.
• W4287218119 cites W2967470003 @default.
• W4287218119 cites W2969391566 @default.
• W4287218119 cites W2969523838 @default.
• W4287218119 cites W2974853946 @default.
• W4287218119 cites W2987000681 @default.
• W4287218119 cites W2987868385 @default.
• W4287218119 cites W2992612707 @default.
• W4287218119 cites W2998804962 @default.
• W4287218119 cites W3004838676 @default.
• W4287218119 cites W3009089560 @default.
• W4287218119 cites W3013214255 @default.
• W4287218119 cites W3015405225 @default.
• W4287218119 cites W3022721765 @default.

• next